tbuckley/cabot-search huggingface dataset:
Decreased myocardial contractility after damage to endocardial endothelium is not merely caused by loss of endothelin production
Authors: G. W. De Keulenaer, P. Fransen, D. L. Brutsaert, S. U. Sys
Journal: Cardiovascular Research (1995)

Journal Article Decreased myocardial contractility after damage to endocardial endothelium is not merely caused by loss of endothelin production Get access Gilles W. De Keulenaer, Gilles W. De Keulenaer Department of Physiology and Medicine, university of Antwerp (RUCA), Groenenborgerlaan 171, 2020 Antwerp, Belgium Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul Fransen, Paul Fransen Department of Physiology and Medicine, university of Antwerp (RUCA), Groenenborgerlaan 171, 2020 Antwerp, Belgium Search for other works by this author on: Oxford Academic PubMed Google Scholar Dirk L. Brutsaert, Dirk L. Brutsaert Department of Physiology and Medicine, university of Antwerp (RUCA), Groenenborgerlaan 171, 2020 Antwerp, Belgium Search for other works by this author on: Oxford Academic PubMed Google Scholar Stanislas U. Sys Stanislas U. Sys * Department of Physiology and Medicine, university of Antwerp (RUCA), Groenenborgerlaan 171, 2020 Antwerp, Belgium *Corresponding author. Tel. (+32-3)218277; Fax (+32-3)2180276. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 30, Issue 5, November 1995, Pages 646–647, https://doi.org/10.1016/S0008-6363(95)00204-9 Published: 01 November 1995
Abstract 1830: Role of heat shock factor 1 (HSF1) on metabolic reprogramming of T -cells
Authors: Bhaumik D. Pandya, Nahid M. Mivechi, Dimitrios Moskophidis
Journal: Cancer Research (2019)

Abstract Heat shock transcription factor 1 (HSF1) is normally activated in response to a variety of environmental stressors. Higher levels of HSF1 expression has been shown in many tumor types and this is associated with poor prognosis. Previous data from our laboratory indicate that genetic inactivation of HSF1 significantly delays ERBB2-induced mammary tumorigenesis and hepatocellular carcinoma induced by chemical carcinogen in mouse models. We have also shown that HSF1 is involved in controlling cellular bioenergetics. CD8-positive T cells plays an important role in anti-tumor immunity response. Our preliminary results show that genetic inactivation of HSF1 in T-cells leads to reduced oxygen consumption rate (OCR) as well as Extracellular Acidification Rate (ECAR). We have also observed that deletion of HSF1 from T cells delayed in-vitro activation of purified CD8-positive T cells upon stimulation with anti-CD3 and anti-CD28. Above characteristics corresponds to reduced cellular glycolysis and T cell proliferation. Further studies will be directed towards exploring the effects of HSF1 deletion in T cell activation induced anti-tumor immunity. This study is supported by the NCI grants; NCICA062130 and NCICA132640. Citation Format: Bhaumik D. Pandya, Nahid M. Mivechi, Dimitrios Moskophidis. Role of heat shock factor 1 (HSF1) on metabolic reprogramming of T -cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1830.
Costs and outcomes for different primary care providers
Authors: D. D. Wright
Journal: JAMA (1977)

This study examined the relationship between levels of medical training and direct costs for 1,700 episodes of acute illness treated in ambulatory-care clinics. Faculty, family practice residents, and physician assistants were included as the providers. Total cost and four component costs were examined. An outcome was defined as good if the patient returned to his usual level of functioning after an acute illness episode. Average total cost per episode was not related to type of provider, but there were significant (P less than .05) differences among providers in laboratory and medication costs. Faculty and physician assistants produced higher costs, especially for patients who experienced bad outcomes. Both costs and percentage of good outcomes achieved were similar in first-, second-, and third-year residents.
INSURANCE OF VEGETARIANS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Die Tuberkulose der Knochen und Gelenke; ihre Pathologie, Diagnostik, Therapie und soziale Bedeutung.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bilateral blue toe syndrome. A case report
Authors: M. W. Rosenberg
Journal: JAMA (1980)

IN 1945, Flory<sup>1</sup>described episodes of multiple emboli of atheromatous material to small arteries. Although these arteries perfused visceral organs, Flory speculated that emboli of cholesterol crystals not only may produce infarcts of visceral organs, but also may be implicated in the production of gangrenous toes or limbs. In 1959, Hoyle et al<sup>2</sup>confirmed this concept clinically when they reported the first case of distal extremity embolization originating from an eroded atherosclerotic plaque. As late as 1976, however, Mehigan and Stoney<sup>3</sup>noted that acute focal ischemia secondary to embolization from nonocclusive atherosclerotic lesions from the arterial tree is frequently overlooked. This article illustrates that repeated attacks of acute ischemic changes evenly distributed to both lower extremities should alert one to consider microemboli as a cause of the problem. <h3>Report of a Case</h3> A 48-year-old man had been admitted to the hospital in 1962 with a long history
Hepatic tocopherol content in primary hepatocellular carcinoma and liver metastases
Authors: E Rocchi, Y Seium, L Camellini, G Casalgrandi, A Borghi, P D'Alimonte, G Cioni
Journal: Hepatology (1997)

The high incidence of hepatocellular carcinoma (HCC) in cirrhosis, where previous studies have indicated a severe reduction in several antioxidant vitamin factors, prompted us to compare plasma liposoluble vitamins with tocopherol content in healthy and neoplastic liver tissue in humans. This, with a view to a more positive preventive dietary approach, given the conflicting results obtained by liposoluble vitamin dietary supplementation in different malignancies. Eleven patients with cirrhosis, 18 patients affected by cirrhosis with HCC, and 10 patients with liver metastases (LM) from digestive tract adenocarcinomas were compared with controls who had undergone perlaparoscopic cholecistectomy. Plasma α- and β-carotene, retinol and tocopherol, together with liver tocopherol, from both nonmalignant portions and malignant nodules of the same organ, were determined by high-performance liquid chromatography following a well-assessed technique. The results confirm a trend towards a reduction in circulating carotenoids and tocopherol in cirrhosis and in patients affected by cirrhosis with HCC. Tocopherol content in liver tissue is significantly decreased in cirrhosis (0.26 + 0.03 μmol/g prot., mean + SEM, P &lt; .001) and in cirrhotic areas of the HCC group (0.31 + 0.02, P &lt; .002), with respect to its content in liver specimens of healthy controls (0.46 + 0.03) and in healthy areas of the same organ in patients with LM (0.41 + 0.03). Tocopherol concentration is further reduced by 50% in malignant liver nodules of HCC, with respect to surrounding cirrhotic tissue, whereas in metastatic liver nodules from digestive neoplasms the tocopherol content is almost twice that of healthy surrounding areas. This unpredictable tocopherol behavior in liver specimens, of secondary as opposed to primary malignancies of the liver, affords further insight into the conflicting effects of liposoluble vitamins employed in the chemopreventive treatment of different malignant diseases, where hepatic tocopherol concentration show opposite trends: halved in primary HCC and doubled in LM of digestive adenocarcinomas, with respect to healthy controls.
Recognition of Illness Associated With the Intentional Release of a Biologic Agent
Journal: JAMA (2001)

and local public health authorities reported a case of inhalational anthrax in Florida. 1 Additional cases of anthrax subsequently have been reported from Florida and New York City.This report updates the findings of these case investigations, which indicate that infections were caused by the intentional release of Bacillus anthracis.This report also includes interim guidelines for postexposure prophylaxis for prevention of inhalational anthrax and other information to assist epidemiologists, clinicians, and laboratorians responding to intentional anthrax exposures.For these investigations, a confirmed case of anthrax was defined as (1) a clinically compatible case of cutaneous, inhalational, or gastrointestinal illness * that is laboratory confirmed by isolation of B. anthracis from an affected tissue or site or ( 2) other laboratory evidence of B. anthracis infection based on at least two supportive laboratory tests.A suspected case was defined as (1) a clinically compatible case of illness without isolation of B. anthracis and no alternative diagnosis, but with laboratory evidence of B. anthracis by one supportive laboratory test or (2) a clinically compatible case of anthrax epidemiologically linked to a confirmed environmental exposure, but without corroborative laboratory evidence of B. anthracis infection.Laboratory criteria for diagnosis of anthrax consist of (1) isolation and confirmation of B. anthracis from a clinical specimen collected from an affected tissue or site or (2) other supportive laboratory tests, including (a) evidence of B. anthracis DNA by polymerase chain reaction (PCR) from specimens collected from an affected tissue or site, (b) demonstration of B. anthracis in a clinical specimen by immunohistochemical staining, or (c) other laboratory tests (e.g., serology) that may become validated by laboratory confirmation.Florida On October 2, the Palm Beach County Health Department (PBCHD) and the Florida Department of Health (FDOH) were notified of a possible anthrax case in Palm Beach County.The suspected case was identified when a gram stain of cerebrospinal fluid (CSF) revealed gram-positive bacilli.An epidemiologic investigation was initiated by FDOH, PBCHD, and the FDOH state laboratory.The state laboratory and CDC confirmed B. anthracis from a culture of CSF on October 4. Later the same day, FDOH and CDC epidemiologists * Ciprofloxacin dosage should not exceed 1 g/d in children.Ciprofloxacin, 500 mg twice per d by mouth Doxycycline, 100 mg twice per d by mouth or or 60 Children Ciprofloxacin, 10-15 mg/kg every 12 h by mouth * Doxycycline Aged >8 y and >45 kg: 100 mg twice per d by mouth Aged >8 y and ≤45 kg: 2.2 mg/kg twice per d by mouth Aged ≤8 y: 2.2 mg/kg twice per d by mouth 60
Nitric oxide stimulates bile flow and glutathione excretion independent of cyclic GMP-induced HCO3- excretion Dept. Medicine and Liver Center, Yale University School of Medicine, New Haven, CT and *Dept. Gastroenterology, Edith Wolfson Medical Center, Holon, Israel
Journal: Hepatology (1995)

Based on studies in the pig, secretin choleresis has been proposed to be initiated by colchicine-inhibitable, exocytic insertion into the basolateral cholangiocyte membrane of intracytoplasmatic vesicles containing a H+ ATPase. Formal prof of this hypothesis in the intact liver of other species, however, is lacking. The effect of the microtubule inhibitor colchicine on the ductular bile formation and HCO−3 secretion induced by secretin was, therefore, explored in a secretin-responsive rat model characterized by marked hyperplasia of bile ductules.While colchicine pretreatment significantly decreased basal bile flow from 142.1±8.8 to 83.4±8.2 μl· min−1·kg−1 (p<0.001) and basal biliary erythritol clearance from 112.7±6.3 to 69.9±7.0 μl·min−1. kg−1 (pš0.05), it did not significantly affect basal biliary [HCO−3], nor basal biliary bile acid output. Moreover, colchicine did not alter the effects of secretin. Thus, the secretin-induced increments in bile flow, biliary [HCO−3] and biliary HCO−3 output averaged 58.2±13.6 μl·min−1·kg−1, 16.6±3.1 mM and 5.3±1.4 μmol·min−1·kg−1 in vehicle-pretreated controls and 78.4±12.0 μl·min−1·kg−1, 16.1±2.7 mM and 5.1±0.5 μmol·min−1·kg−1 in colchicine-pretreated animals (all p values=n.s), respectively. This suggests that, at least in the rat model used, microtubule-dependent mechanisms are involved in basal, bile acid independent canalicular, but not in secretin-induced ductular, bile formation. Inasmuch as microtubule-dependent mechanisms are required for vesicle movement, this argues strongly against an absolute requirement for exocytic vesicle insertion in the ductular choleresis induced by secretin.
Academic Radiology.
Authors: Enrique Pantoja
Journal: JAMA (1997)

In 1994 the three leading academic radiology societies in the United States, along with their counterpart among radiology residents, severed a long relationship with<i>Investigative Radiology</i>and its publisher JB Lippincott (now Lippincott-Raven) to found their own journal.<i>Academic Radiology</i>serves as the official journal of the Association of University Radiologists, the Society of Chairmen of Academic Radiology Departments, the Association of Program Directors in Radiology, and the American Association of Academic Chief Residents in Radiology. The scope of this publication encompasses original clinical and laboratory investigations, educational research, administrative and health policy issues, and recent advances in radiology. The editors include nationally known members of the constituent societies. In addition, distinguished representatives of academic radiology from Australia, Japan, and western Europe serve as corresponding editors. Each issue of<i>Academic Radiology</i>contains five to seven original investigative articles. Other regular features include Preliminary Investigations, Administration and Management, Radiological Education
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring <i>FGFR3</i> alterations.
Authors: Sumanta K. Pal, Siamak Daneshmand, Surena F. Matin, Yohann Loriot, Srikala S. Sridhar, Petros Grivas, Shilpa Gupta, Guru Sonpavde, Mark T. Fleming, Seth P. Lerner, Craig Berman, Jessica Rearden, Yining Ye, Hiywot Takkele, Susan Moran, Joaquim Bellmunt
Journal: Journal of Clinical Oncology (2020)

TPS600 Background: Radical surgery ± cisplatin‐based (neo)adjuvant therapy (NAT) is the mainstay of treatment for invasive urothelial carcinoma of the upper urinary tract (UTUC) or bladder (UBC), but recurrence rates are high. Furthermore, many patients (pts) are unable to receive NAT because of cisplatin ineligibility. Fibroblast growth factor receptor 3 (FGFR3) genetic alterations occur in up to 70% of UTUC and up to 20% of UBC, and may constitute a potential candidate for targeted therapy. Infigratinib (BGJ398), a selective FGFR1–3 inhibitor, has shown promising clinical activity and tolerability in pts with advanced urothelial carcinoma having FGFR3 alterations [Pal et al. Cancer Discov 2018]. PROOF 302 has been designed to investigate the efficacy and safety of infigratinib versus placebo as adjuvant therapy in pts with high-risk invasive urothelial carcinoma and FGFR3 alterations. Methods: PROOF 302 is a randomized, double-blind, placebo-controlled, phase III study of approx. 218 pts. Adults with high-risk invasive UTUC or UBC with FGFR3 genetic alterations (i.e. mutations, gene fusions or translocations) who are ≤120 days following surgical resection and ineligible for cisplatin-based adjuvant chemotherapy or with residual disease after cisplatin- based NAT are eligible. Those who received non cisplatin-based NAT are eligible if they have residual disease and are ineligible for adjuvant cisplatin. Pts receive oral infigratinib 125 mg or placebo (1:1 ratio) once daily on days 1–21 every 28 days for up to 52 weeks or until disease recurrence, unacceptable toxicity or death. Primary endpoint: centrally reviewed disease-free survival (DFS). Secondary endpoints: DFS including intraluminal low-risk recurrence; metastasis-free survival; overall survival; DFS (per investigator); safety and tolerability. Exploratory endpoints include: quality of life; pharmacokinetics; cell-free DNA (cfDNA) and/or RNA for resistance mechanisms. The study will involve approximately 120 centers worldwide. Enrollment is expected to begin in January 2020. Trial registration: EudraCT 2019-003248-63. Clinical trial information: EudraCT 2019-003248-63.
Treatment of Arterial Occlusion Under Oxygen at Two-Atmospheres Pressure
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Osteomyelitis involving adjacent ribs
Authors: J. L. Guest
Journal: JAMA (1978)

EVEN before the advent of antibiotics, osteomyelitis of a rib has been rare. In the following case, the unusual roentgenographic appearance and the involvement of more than one rib created an interesting problem in diagnosis and management. <h3>Report of a Case</h3> A 14-year-old boy was admitted with a draining sinus in the chest wall of six months' duration. At the time of onset a small, tender area appeared just beneath the left nipple. After several days the center of the lesion drained spontaneously. A malodorous discharge persisted despite antibiotic therapy. After obtaining an abnormal chest roentgenogram, his local physician referred him for further examination. The patient denied chest trauma, exposure to tuberculosis, furunculosis, or any other infectious disease in the recent or distant past. On physical examination the patient was afebrile and did not appear ill. There were no abnormal physical findings except for a slightly tender sinus opening just
The Lock-Jaw of Infants (Trismus Nascentium) or Nine-Day Fits, Crying Spasms, etc.; Its History, Cause, Prevention and Cure.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
J Pharmacol &amp;amp; Exper Therapeutics, Baltimore
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal